These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 26022732)

  • 1. Neonatal Systemic AAV Induces Tolerance to CNS Gene Therapy in MPS I Dogs and Nonhuman Primates.
    Hinderer C; Bell P; Louboutin JP; Zhu Y; Yu H; Lin G; Choa R; Gurda BL; Bagel J; O'Donnell P; Sikora T; Ruane T; Wang P; Tarantal AF; Casal ML; Haskins ME; Wilson JM
    Mol Ther; 2015 Aug; 23(8):1298-1307. PubMed ID: 26022732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safe and Sustained Expression of Human Iduronidase After Intrathecal Administration of Adeno-Associated Virus Serotype 9 in Infant Rhesus Monkeys.
    Hordeaux J; Hinderer C; Buza EL; Louboutin JP; Jahan T; Bell P; Chichester JA; Tarantal AF; Wilson JM
    Hum Gene Ther; 2019 Aug; 30(8):957-966. PubMed ID: 31017018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neonatal tolerance induction enables accurate evaluation of gene therapy for MPS I in a canine model.
    Hinderer C; Bell P; Louboutin JP; Katz N; Zhu Y; Lin G; Choa R; Bagel J; O'Donnell P; Fitzgerald CA; Langan T; Wang P; Casal ML; Haskins ME; Wilson JM
    Mol Genet Metab; 2016 Sep; 119(1-2):124-30. PubMed ID: 27386755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal Adeno-Associated Virus Mediated Gene Delivery and Expression of Human Iduronidase in the Central Nervous System: A Noninvasive and Effective Approach for Prevention of Neurologic Disease in Mucopolysaccharidosis Type I.
    Belur LR; Temme A; Podetz-Pedersen KM; Riedl M; Vulchanova L; Robinson N; Hanson LR; Kozarsky KF; Orchard PJ; Frey WH; Low WC; McIvor RS
    Hum Gene Ther; 2017 Jul; 28(7):576-587. PubMed ID: 28462595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrastromal Gene Therapy Prevents and Reverses Advanced Corneal Clouding in a Canine Model of Mucopolysaccharidosis I.
    Miyadera K; Conatser L; Llanga TA; Carlin K; O'Donnell P; Bagel J; Song L; Kurtzberg J; Samulski RJ; Gilger B; Hirsch ML
    Mol Ther; 2020 Jun; 28(6):1455-1463. PubMed ID: 32330426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human alpha-L-iduronidase gene.
    Hartung SD; Frandsen JL; Pan D; Koniar BL; Graupman P; Gunther R; Low WC; Whitley CB; McIvor RS
    Mol Ther; 2004 Jun; 9(6):866-75. PubMed ID: 15194053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrathecal administration of AAV vectors for the treatment of lysosomal storage in the brains of MPS I mice.
    Watson G; Bastacky J; Belichenko P; Buddhikot M; Jungles S; Vellard M; Mobley WC; Kakkis E
    Gene Ther; 2006 Jun; 13(11):917-25. PubMed ID: 16482204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrathecal gene therapy corrects CNS pathology in a feline model of mucopolysaccharidosis I.
    Hinderer C; Bell P; Gurda BL; Wang Q; Louboutin JP; Zhu Y; Bagel J; O'Donnell P; Sikora T; Ruane T; Wang P; Haskins ME; Wilson JM
    Mol Ther; 2014 Dec; 22(12):2018-2027. PubMed ID: 25027660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved retroviral vector design results in sustained expression after adult gene therapy in mucopolysaccharidosis I mice.
    Herati RS; Ma X; Tittiger M; Ohlemiller KK; Kovacs A; Ponder KP
    J Gene Med; 2008 Sep; 10(9):972-82. PubMed ID: 18613275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limited transgene immune response and long-term expression of human alpha-L-iduronidase in young adult mice with mucopolysaccharidosis type I by liver-directed gene therapy.
    Di Domenico C; Di Napoli D; Gonzalez Y Reyero E; Lombardo A; Naldini L; Di Natale P
    Hum Gene Ther; 2006 Nov; 17(11):1112-21. PubMed ID: 17044753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correction of clinical manifestations of canine mucopolysaccharidosis I with neonatal retroviral vector gene therapy.
    Traas AM; Wang P; Ma X; Tittiger M; Schaller L; O'donnell P; Sleeper MM; Vite C; Herati R; Aguirre GD; Haskins M; Ponder KP
    Mol Ther; 2007 Aug; 15(8):1423-31. PubMed ID: 17519893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Highly Efficacious PS Gene Editing System Corrects Metabolic and Neurological Complications of Mucopolysaccharidosis Type I.
    Ou L; Przybilla MJ; Ahlat O; Kim S; Overn P; Jarnes J; O'Sullivan MG; Whitley CB
    Mol Ther; 2020 Jun; 28(6):1442-1454. PubMed ID: 32278382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucopolysaccharidosis I cats mount a cytotoxic T lymphocyte response after neonatal gene therapy that can be blocked with CTLA4-Ig.
    Ponder KP; Wang B; Wang P; Ma X; Herati R; Wang B; Cullen K; O'Donnell P; Ellinwood NM; Traas A; Primeau TM; Haskins ME
    Mol Ther; 2006 Jul; 14(1):5-13. PubMed ID: 16698321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene therapy for canine alpha-L-iduronidase deficiency: in utero adoptive transfer of genetically corrected hematopoietic progenitors results in engraftment but not amelioration of disease.
    Lutzko C; Omori F; Abrams-Ogg AC; Shull R; Li L; Lau K; Ruedy C; Nanji S; Gartley C; Dobson H; Foster R; Kruth S; Dubé ID
    Hum Gene Ther; 1999 Jun; 10(9):1521-32. PubMed ID: 10395377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delivery of an Adeno-Associated Virus Vector into Cerebrospinal Fluid Attenuates Central Nervous System Disease in Mucopolysaccharidosis Type II Mice.
    Hinderer C; Katz N; Louboutin JP; Bell P; Yu H; Nayal M; Kozarsky K; O'Brien WT; Goode T; Wilson JM
    Hum Gene Ther; 2016 Nov; 27(11):906-915. PubMed ID: 27510804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AAV Gene Therapy for MPS1-associated Corneal Blindness.
    Vance M; Llanga T; Bennett W; Woodard K; Murlidharan G; Chungfat N; Asokan A; Gilger B; Kurtzberg J; Samulski RJ; Hirsch ML
    Sci Rep; 2016 Feb; 6():22131. PubMed ID: 26899286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Endovascular and Intraventricular Gene Therapy With Adeno-Associated Virus-α-L-Iduronidase for Hurler Disease.
    Janson CG; Romanova LG; Leone P; Nan Z; Belur L; McIvor RS; Low WC
    Neurosurgery; 2014 Jan; 74(1):99-111. PubMed ID: 24077583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver-directed gene therapy corrects cardiovascular lesions in feline mucopolysaccharidosis type I.
    Hinderer C; Bell P; Gurda BL; Wang Q; Louboutin JP; Zhu Y; Bagel J; O'Donnell P; Sikora T; Ruane T; Wang P; Haskins ME; Wilson JM
    Proc Natl Acad Sci U S A; 2014 Oct; 111(41):14894-9. PubMed ID: 25267637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neonatal gene therapy of MPS I mice by intravenous injection of a lentiviral vector.
    Kobayashi H; Carbonaro D; Pepper K; Petersen D; Ge S; Jackson H; Shimada H; Moats R; Kohn DB
    Mol Ther; 2005 May; 11(5):776-89. PubMed ID: 15851016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting a Pre-existing Anti-transgene T Cell Response for Effective Gene Therapy of MPS-I in the Mouse Model of the Disease.
    Squeri G; Passerini L; Ferro F; Laudisa C; Tomasoni D; Deodato F; Donati MA; Gasperini S; Aiuti A; Bernardo ME; Gentner B; Naldini L; Annoni A; Biffi A; Gregori S
    Mol Ther; 2019 Jul; 27(7):1215-1227. PubMed ID: 31060789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.